Semaglutide Nearly Doubles MASH Resolution Rate but Falls Short on Liver Fibrosis in Meta-Analysis of 32,000 Patients | Research

The takeaway

A meta-analysis of 22 RCTs and 32,013 patients found semaglutide nearly doubled MASH resolution rates and reduced liver fat, enzymes, and mortality — but did not significantly improve liver fibrosis regression.

RR 1.98 for MASH resolution
Semaglutide nearly doubled the rate of MASH resolution compared to placebo across 32,013 patients, while also reducing all-cause mortality by 18% — but liver fibrosis regression remained non-significant.

What the researchers found

Across 22 RCTs and 32,013 patients:

- MASH Resolution: significantly improved (RR 1.98, 95% CI: 1.57-2.50) — nearly doubling the resolution rate

- Fibrosis Regression: NOT significantly improved (RR 1.18, 95% CI: 0.74-1.88)

- Liver Steatosis: reduced by 11.3% (95% CI: -18.70 to -3.91)

- ELF score (fibrosis marker): reduced by 0.49 (95% CI: -0.70 to -0.29)

- ALT: reduced by 5.55 U/L; AST: reduced by 3.85 U/L

- All-cause mortality: reduced 18% (RR 0.82, 95% CI: 0.74-0.91)

- Cardiovascular risk: reduced 17% (RR 0.83, 95% CI: 0.75-0.92)

- Best results at doses ≥2.0 mg weekly and durations ≥12 months

Why it matters

MASH is expected to become the leading cause of liver transplantation worldwide, and until recently there were almost no approved pharmacotherapies. Semaglutide's ability to resolve MASH in nearly twice as many patients as placebo is clinically significant. However, the failure to improve fibrosis — the key driver of cirrhosis, liver failure, and death — is an important limitation that must temper enthusiasm. The mortality and cardiovascular benefits add independent value, but for patients with advanced fibrosis, semaglutide alone may not be sufficient.

How the study worked

Systematic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov through August 2025 for randomized controlled trials of semaglutide in MASH patients. Twenty-two RCTs with 32,013 patients were included. PRISMA guidelines were followed. Outcomes included MASH resolution, fibrosis regression, liver steatosis, ELF score, liver enzymes (ALT, AST), weight, glycemic and lipid parameters, all-cause mortality, and cardiovascular risk. Subgroup analyses assessed dose-response (dose ≥2.0 mg vs. lower) and duration-response (≥12 months vs. shorter) relationships.

What this study cannot tell us

The 22 included RCTs likely varied in patient populations, semaglutide formulations (subcutaneous vs. oral), doses, and MASH severity, introducing heterogeneity. The fibrosis outcome was not statistically significant, but the confidence interval was wide (0.74-1.88), suggesting the analysis may have been underpowered for this endpoint. Many included trials may have enrolled patients based on metabolic criteria rather than biopsy-confirmed MASH. The mortality and cardiovascular benefits come largely from cardiovascular outcomes trials that included MASH as a secondary population, not from MASH-specific trials.

How to read the evidence

This is a PRISMA-compliant meta-analysis of 22 randomized controlled trials including over 32,000 patients — representing the highest level of clinical evidence available. The large sample size and consistent methodology strengthen the conclusions, though the fibrosis outcome's non-significance and heterogeneity across trials are important caveats.

When this study was published

Published in 2025 with literature searched through August 2025, this is an extremely current meta-analysis capturing the latest RCT data on semaglutide in MASH.

The bigger picture

Semaglutide is one of several drugs racing to treat MASH — resmetirom (a thyroid hormone receptor agonist) was the first FDA-approved MASH drug, specifically for its anti-fibrotic effects. This meta-analysis positions semaglutide as complementary: strong for inflammation resolution and metabolic improvement but limited for fibrosis. A combination approach — semaglutide for metabolic/inflammatory control plus a fibrosis-targeted agent — may become the standard of care. The mortality benefit is particularly noteworthy and may justify semaglutide use in MASH patients regardless of fibrosis effects.

Questions still open

Would combining semaglutide with a fibrosis-targeted drug like resmetirom provide comprehensive MASH treatment?
Is the 18% mortality reduction driven by cardiovascular protection, liver improvement, or both?
Would higher semaglutide doses (e.g., 7.2 mg weekly, as tested in obesity trials) produce significant fibrosis improvement?

Common questions

Can semaglutide cure fatty liver disease?

Semaglutide can resolve the inflammatory component of fatty liver disease (MASH) in about twice as many patients as placebo, and it significantly reduces liver fat and liver enzymes. However, it doesn't significantly reverse liver scarring (fibrosis), which is the main driver of liver failure and the need for transplant. It works best at higher doses (2+ mg weekly) for at least 12 months.

Should I take semaglutide if I have MASH?

This large analysis supports semaglutide as beneficial for MASH — it resolves liver inflammation, reduces fat, and lowers death risk by 18%. However, if your main concern is liver fibrosis, semaglutide alone may not be enough. Talk to your doctor about whether semaglutide — possibly combined with other treatments — is right for your specific situation.

Read the original research

The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.

Diabetology & metabolic syndrome, 17(1), 439

View on PubMed ↗Publisher’s paper ↗

Citation

Kan, Ranran; Wang, Siyi; Meng, Xiaoyu; Guo, Yaming; Li, Danpei; Yu, Xuefeng. (2025). The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.. Diabetology & metabolic syndrome, 17(1), 439. https://doi.org/10.1186/s13098-025-01995-z